Treat-And-Extend Versus Monthly Regimen in Neovascular Age-Related Macular Degeneration

Ophthalmology - Netherlands
doi 10.1016/j.ophtha.2017.07.014
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Elsevier BV

Related search

Switching Frompro Re Natato Treat-And-Extend Regimen Improves Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2017English

Outcomes When Switching From a Pro Re Nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration

Ophthalmologica
MedicineOphthalmologySensory Systems
2016English

Treat-And-Extend Versus Every-Other-Month Regimens With Aflibercept in Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2017English

Comment on ‘Transitioning to Intravitreal Aflibercept Following a Previous Treat-And-Extend Dosing Regimen in Neovascular Age-Related Macular Degeneration: 24-Month Results’

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2015English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Low-Energy Stereotactic Radiotherapy for Treatment of Exudative Age-Related Macular Degeneration in a Treat-And-Extend Regimen

Ophthalmic Surgery Lasers and Imaging Retina
MedicineOphthalmologySurgery
2018English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Treat-And-Extend Therapy Using Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: 2-Year Real-World Practice Data From Slovenia

BMC Ophthalmology
MedicineOphthalmology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy